Cynomolgus GITR/TNFRSF18 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Cynomolgus GITR/TNFRSF18 Protein is expressed from HEK293 with His tag at the C-Terminus.
It contains Gln20-Pro156 [Accession | XP_005545180.2].

分子量大小(Molecular Weight)

The protein has a predicted MW of 15.87 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Cynomolgus GITR on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Cynomolgus GITR, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-GITR Antibody, hFc Tag with the EC50 of 7.6ng/ml determined by ELISA (QC Test).

SPR Data

Cynomolgus GITR Ligand, His Tag immobilized on CM5 Chip can bind Cynomolgus GITR, His Tag with an affinity constant of 0.21 μM as determined in SPR assay (Biacore T200).

背景(Background)

GITR (glucocorticoid-induced tumor necrosis factor receptor), also known as AITR and TNFRSF18, is a 40 kDa transmembrane glycoprotein that functions in immune regulation.GIRT is a receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway.

分子别名(Synonyms)

CD357; GITR; GITR-D; TNFRSF18; AITR

文献(References)

(1)Knee D A , Hewes B , Brogdon J L. Rationale for anti-GITR cancer immunotherapy[J]. European Journal of Cancer, 2016, 67:1-10.